TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018
|Conference call and webcast:|
|Date:||February 28, 2018|
|Time:||4:30 pm Eastern Time (1:30 pm Pacific Time)|
|Dial-in:||(855) 779-9066 (Domestic) or (631) 485-4859 (International)|
|Via web:||www.traconpharma.com; “Events and Presentation” section within the “Investors” section|
A replay of the webcast will be available for 60 days on the website.
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Chief Business Officer
(858) 550-0780 ext. 236
LifeSci Advisors LLC
Source: TRACON Pharmaceuticals, Inc.